STSA 0.00 Satsuma Pharmaceuticals, Inc.
| Range: | 0.59-8.08 | Vol Avg: | 1106610 | Last Div: | 1.5 | Changes: | 0 |
| Beta: | 0.1 | Cap: | 0.04B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Sep 13 2019 | Empoloyees: | 25 | ||
| CUSIP: | 80405P107 | CIK: | 0001692830 | ISIN: | US80405P1075 | Country: | US |
| CEO: | Mr. John A. Kollins MBA | Website: | https://www.satsumarx.com | ||||
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow